Benitec Biopharma Inc. (NASDAQ: BNTC)
$10.15
+0.6800 ( +7.18% ) 45.5K
Benitec Biopharma Inc is a biotechnology company developing a proprietary therapeutic technology platform that combines RNA interference with gene therapy for providing sustained, long-lasting silencing of disease-causing genes from a single administration. Its technology has the potential to provide a one-shot cure for a wide range of diseases that are addressed by strict ongoing treatment regimens or that have no effective treatment or only palliative care options. The company is developing product candidates in chronic and life-threatening human disease areas including Orphan disease: Oculopharyngeal Muscular Dystrophy (OPMD) and Infectious disease: Hepatitis B Virus (HBV). BB-301 is currently under development by the group; it is designed to slow, or halt, the disease progression.
Market Data
Open
$10.15
Previous close
$9.47
Volume
45.5K
Market cap
$95.55M
Day range
$9.38 - $10.26
52 week range
$1.86 - $10.70
SEC Fillings
Form Type | Description | Pages | Date |
---|---|---|---|
def | Proxies and info statements | 26 | Oct 20, 2023 |
8-k | 8K-related | 12 | Oct 16, 2023 |
8-k | 8K-related | 12 | Sep 28, 2023 |
10-k | Annual reports | 100 | Sep 21, 2023 |
8-k | 8K-related | 13 | Sep 21, 2023 |
8-k | 8K-related | 12 | Sep 18, 2023 |
4 | Insider transactions | 1 | Aug 14, 2023 |
4 | Insider transactions | 1 | Aug 14, 2023 |
8-k | 8K-related | 18 | Aug 11, 2023 |
8-k | 8K-related | 12 | Aug 10, 2023 |